72 related articles for article (PubMed ID: 24116377)
21. Antitumor activity of common antibiotics against superficial bladder cancer.
Kamat AM; Lamm DL
Urology; 2004 Mar; 63(3):457-60. PubMed ID: 15028437
[TBL] [Abstract][Full Text] [Related]
22. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
24. Enhancing the photodynamic effect of hypericin in human bladder transitional cell carcinoma spheroids by the use of the oxygen carrier, perfluorodecalin.
Kamuhabwa AR; Huygens A; Roskams T; De Witte PA
Int J Oncol; 2006 Mar; 28(3):775-80. PubMed ID: 16465384
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.
Knapp DW; Henry CJ; Widmer WR; Tan KM; Moore GE; Ramos-Vara JA; Lucroy MD; Greenberg CB; Greene SN; Abbo AH; Hanson PD; Alva R; Bonney PL
J Vet Intern Med; 2013; 27(1):126-33. PubMed ID: 23205923
[TBL] [Abstract][Full Text] [Related]
26. Modulating effect of mitomycin or cisplatin on lymphokine-activated killer cell proliferation and antitumor activity to bladder cancer cell lines in vitro.
Wang ZP; Qing DS; Shi BG; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):369-72. PubMed ID: 10375787
[TBL] [Abstract][Full Text] [Related]
27. Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein.
Kondo Y; Yamagata K; Satoh M; Himeno S; Imura N; Nishimura T
J Urol; 2003 Dec; 170(6 Pt 1):2467-70. PubMed ID: 14634452
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Cytotoxic Effect from Combination of Wedelolactone and Cisplatin in HeLa Cell Line: A Novel Finding.
Sarwar S; Yu JQ; Nadeem H; Huq F
Drug Des Devel Ther; 2020; 14():3841-3852. PubMed ID: 33061291
[TBL] [Abstract][Full Text] [Related]
29. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
31. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
32. Increasing the cisplatin cytotoxicity and cisplatin-induced DNA damage by conferone in 5637 cells.
Neshati V; Matin MM; Bahrami AR; Iranshahi M; Rassouli FB; Saeinasab M
Nat Prod Res; 2012; 26(18):1724-7. PubMed ID: 21988674
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
Culine S
Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527
[No Abstract] [Full Text] [Related]
34. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
37. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
[TBL] [Abstract][Full Text] [Related]
38. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E
Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.
Arantes-Rodrigues R; Pinto-Leite R; Fidalgo-Gonçalves L; Palmeira C; Santos L; Colaço A; Oliveira P
Biomed Res Int; 2013; 2013():791406. PubMed ID: 24369536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
